U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility

Bristol-Myers Squibb Company

announced today that the U.S. Food and Drug Administration (FDA) has approved the company's biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA^® (abatacept). The Devens facility, a state-of-the-art bulk biologics manufacturing facility, employs roughly 300 scientists, engineers, bioprocess operators, quality specialists and other skilled workers.